Amylyx Pharmaceuticals (AMLX) Profit After Tax (2021 - 2026)

Amylyx Pharmaceuticals' Profit After Tax history runs 6 years deep, the most recent figure standing at -$41.3 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 14.97% year-over-year to -$41.3 million; the TTM figure through Mar 2026 stood at -$150.1 million (up 31.41% YoY), while the FY2025 annual figure was -$144.7 million, up 52.03% from the prior year.
• Profit After Tax was -$41.3 million for Q1 2026 at Amylyx Pharmaceuticals, down from -$33.0 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $22.1 million in Q2 2023 to a low of -$118.8 million in Q1 2024.
• Historically, Profit After Tax has averaged -$37.5 million across 5 years, with a median of -$41.3 million in 2026.
• The sharpest annual moves came in 2023 and 2024: Profit After Tax surged 140.83% in 2023, then plunged 7652.0% in 2024.
• A 5-year view of Profit After Tax shows it stood at -$42.7 million in 2022, then jumped by 111.08% to $4.7 million in 2023, then plunged by 893.62% to -$37.5 million in 2024, then rose by 12.11% to -$33.0 million in 2025, then retreated by 25.11% to -$41.3 million in 2026.
• The last three Profit After Tax figures came in at -$41.3 million (Q1 2026), -$33.0 million (Q4 2025), and -$34.4 million (Q3 2025), per Business Quant data.